Abstract | INTRODUCTION: METHODS: BALB/c mice were sensitized and challenged with ovalbumin to develop a murine model of allergic airway inflammation mimicking human atopic asthma. During the challenge phase, mice were treated with or without tiotropium. Lung cells were isolated 24 h after the last treatment and gated using CD68-positive cells. Relm-α and Arginase-1 (Arg1) (M2 macrophage markers) expression was determined by flow cytometry. Mouse bone marrow mononuclear cell-derived macrophages (mBMMacs) and human peripheral blood mononuclear cells (PBMCs)-derived macrophages were stimulated with IL-4 and treated with a muscarinic M3 receptor antagonist in vitro. RESULTS: The total cells, eosinophils, and IL-5 and IL-13 levels in BAL fluids were markedly decreased in the asthma group treated with tiotropium compared to that in the untreated asthma group. The Relm-α and Arg1 expression in macrophages was reduced considerably in the asthma group treated with tiotropium compared to that in the untreated asthma group, suggesting that the development of M2 macrophages was inhibited by muscarinic M3 receptor blockage. Additionally, muscarinic M3 receptor blockage in vitro significantly inhibited M2 macrophage development in both mBMMacs- and PBMCs-derived macrophages. CONCLUSIONS:
|
Authors | Megumi Jinno, Shin Ohta, Hatsuko Mikuni, Tomoki Uno, Yoshitaka Uchida, Ryo Manabe, Yoshito Miyata, Tetsuya Homma, Yoshio Watanabe, Sojiro Kusumoto, Shintaro Suzuki, Akihiko Tanaka, Hironori Sagara |
Journal | International archives of allergy and immunology
(Int Arch Allergy Immunol)
Pg. 1-10
(Apr 02 2024)
ISSN: 1423-0097 [Electronic] Switzerland |
PMID | 38565078
(Publication Type: Journal Article)
|
Copyright | © 2024 S. Karger AG, Basel. |